Probiotics alongside GLP-1 medicines: what the evidence shows on muscle, nausea and weight regain

Probiotics are being pitched as the next GLP-1 companion: something to protect muscle while semaglutide or tirzepatide strips weight, calm the nausea of dose increases, or stop the regain when the injections end. On 5 November 2026 a Nasdaq-listed company reported that its engineered probiotic, given with semaglutide, produced greater absolute lean mass in obese mice. Two other strain studies published this year make similar claims for weight regain.

Short answer: every published muscle-preservation result for a probiotic alongside a GLP-1 medicine comes from mice. No completed human trial has reported a muscle or lean-mass result. A completed trial in Poland measured gut symptoms and weight, and it has not posted results. A French trial that is still recruiting includes lean mass and skeletal muscle mass, and it has no results yet. If protecting muscle is the goal, protein and resistance training have far better support than any capsule.

Why muscle is the selling point

GLP-1 medicines cause some loss of lean tissue along with fat. A 2026 meta-analysis in Drugs of 60 studies (46 randomised trials, 13 real-world studies and one pharmacovigilance study) found a consistent fall in lean body mass or fat-free mass with GLP-1 receptor agonists, mainly driven by liraglutide and semaglutide. The authors rated the certainty of evidence as low, said the change appeared largely related to weight loss, and said it is uncertain whether it translates into worse muscle function. A 2026 review in Metabolites adds that lean mass measured by DXA or bioimpedance is not the same as skeletal muscle, and that lean-tissue loss does not necessarily mean weaker muscles.

That uncertainty is the gap probiotic marketing steps into. The same Metabolites review concludes that the most defensible support combines food-first nutrition advice, adequate protein, structured resistance exercise, management of gut side effects and monitoring for micronutrient shortfalls. It lists probiotics among adjunctive options supported mainly by indirect or phenotype-specific evidence.

The new mouse results

• EL-32 (NorthStrive Biosciences, 5 November 2026). An eight-week study in diet-induced obese mice. The highest EL-32 dose with semaglutide gave greater absolute lean mass than semaglutide alone, but no significant difference in relative lean mass, and the result was not reproduced at the lower combination dose. The company says the combination did not show a consistent additive metabolic benefit, EL-32 alone did not meaningfully improve body weight or body composition, and the findings do not establish efficacy or muscle preservation in humans. EL-32 is an investigational engineered probiotic from a biopharmaceutical company, designed to target myostatin and activin A; it is not a shop product. The company plans a further preclinical study using a lower semaglutide dose, which has not started, and expects to give an update on its design and timing in the first quarter of 2027.
• Limosilactobacillus fermentum GB102 (Nutrients, March 2026). In obese mice given dulaglutide for four weeks and then taken off it, the strain enhanced weight loss, preserved muscle strength and reduced weight and blood-sugar rebound. Six of the seven authors work for probiotic or biotech companies (GI Longevity, Mediogen and GI Innovation).
• L. paracasei LP-18 (Metabolites, 30 October 2026). Mice lost weight on semaglutide for four weeks, then stopped it and received LP-18 or a dummy for four weeks, with seven mice per group. LP-18 mice regained less weight and ate less in total. The mice stayed on a high-fat diet throughout, and every author is employed by Moon (Guangzhou) Biotech, which funded the work. The authors state that whether the findings apply to humans awaits clinical trials.
• Akkermansia muciniphila Akk11 (Cell & Bioscience, January 2026). In diabetic db/db mice, adding Akk11 to semaglutide reduced fat and improved liver histology compared with semaglutide alone. One co-author lists an affiliation with Wecare Probiotics.

Mouse studies are where ideas start, not where they are proved. These are small, short mouse experiments, and none measured muscle in people. The NorthStrive, GB102 and LP-18 studies used high-fat diets and were run or funded by the companies developing the strains. The Akk11 study used diabetic db/db mice.

What human trials exist

• Dulaglutide plus Bifidobacterium longum (Hormones, 2025). Sixty adults with type 2 diabetes and overweight or obesity in a trial run by researchers at Zhangjiakou First Hospital, China, took dulaglutide 1.5 mg weekly with a probiotic or a placebo for 12 weeks. HbA1c fell by 1.06% with the probiotic versus 0.35% with placebo (P = 0.028). It reported no muscle or body-composition outcome.
• Gut side effects on semaglutide (NCT07847593, Poland). A double-blind trial sponsored by Nordic Biotic randomised 102 adults with obesity to a four-strain probiotic or maltodextrin, starting two weeks before semaglutide and continuing through 12 weeks of dose escalation. The primary outcome is gastrointestinal adverse events; body weight and treatment discontinuation are secondary. The registry lists the study as completed, with primary completion in July 2026, and no results posted.
• Digestive quality of life (NCT07213323, France). Hospices Civils de Lyon is recruiting about 50 adults starting semaglutide or tirzepatide for a 26-week placebo-controlled study of digestive quality of life, with primary completion estimated for December 2027. Secondary outcomes include fat mass, lean mass and skeletal muscle mass. There are no results yet.
• Weight after stopping (NCT07209046). Metagenics registered a 128-person, app-based trial of a product combining Bifidobacterium lactis B420 and pasteurised Akkermansia muciniphila in adults who have stopped GLP-1 treatment, with weight at 12 weeks as the primary outcome. The registry still lists it as not yet recruiting.

The nearest proof of concept for regain is not a GLP-1 study at all. In a Nature Medicine trial published in May 2026, 90 adults lost at least 8% of body weight on an eight-week low-energy diet and then took pasteurised Akkermansia muciniphila MucT or placebo for 24 weeks. Regain was 1.2 kg versus 3.2 kg (P = 0.012), with no treatment-related serious adverse events. Several authors work for or advise The Akkermansia Company, and four are inventors on a related patent application. An earlier 2019 pilot of 32 completers found better insulin sensitivity with pasteurised A. muciniphila, but the weight difference from placebo (2.27 kg) was not statistically significant.

Why regain is the real question

Weight regain after stopping GLP-1 medicines is large and follows a predictable pattern. A 2026 meta-regression of six randomised trials with 3,236 participants estimated that 60% of the weight lost on treatment is regained one year after stopping. Beyond one year the same model is an extrapolation, and it levels off at about 75% (95% confidence interval 68.9% to 81.6%). A cheap, safe way to soften that curve would matter far more than marginal lean-mass gains in mice. That is why the regain trials are worth watching, and why their absence of published results is the honest status today.

Our view

• Do not buy a probiotic to protect muscle on a GLP-1 medicine. No published human result has measured that. A French trial that is still recruiting will measure lean mass and skeletal muscle mass, and it has no results.
• Prioritise adequate protein and regular resistance training as part of the package the 2026 Metabolites review calls most defensible: food-first nutrition advice, adequate protein, structured resistance exercise, management of gut side effects, and checks for micronutrient shortfalls. Ask the prescriber about body-composition or strength monitoring if muscle loss worries you.
• If nausea, constipation or diarrhoea are the problem, tell the prescriber first; managing gut side effects is part of standard supportive care. A probiotic has not been shown to help those symptoms. The first placebo-controlled data are expected from the Polish trial once it reports.
• Be wary of any product that promises to "boost" a GLP-1 medicine or replace it. Strain-specific results in mice do not transfer to a different strain in a capsule.

South African rules

SAHPRA's public information states that, under the Medicines and Related Substances Act 101 of 1965, any product intended to treat, prevent or alter bodily functions must be registered with SAHPRA before it can be sold in South Africa. SAHPRA has also warned the public about GLP-1 products sold through social media. A probiotic marketed as a GLP-1 booster or substitute belongs under that scrutiny. Side effects can be reported to adr@sahpra.org.za.

FAQ

Do probiotics protect muscle on semaglutide or tirzepatide?

There is no human evidence that they do. The muscle results so far come from mouse studies, and one of the newest found greater absolute lean mass only at the highest dose, with no difference in relative lean mass.

Can probiotics reduce GLP-1 nausea or other gut side effects?

Not yet shown. A completed 102-person placebo-controlled trial in Poland measured exactly this during semaglutide dose escalation, but results have not been posted. A French trial in people starting semaglutide or tirzepatide is still recruiting.

Do probiotics stop weight regain after stopping a GLP-1 medicine?

Mouse studies suggest some strains blunt regain. In people, the best evidence is a diet-based Nature Medicine trial in which pasteurised Akkermansia reduced regain by about 2 kg over 24 weeks, which did not involve GLP-1 medicines. A trial after GLP-1 discontinuation is registered but not yet recruiting.

Are probiotics safe to take with a GLP-1 medicine?

The published randomised trial of a probiotic with a GLP-1 medicine summarised here (dulaglutide, 60 people, 12 weeks) reported both regimens as well tolerated, but it was small and short. Tell your prescriber or pharmacist about any supplement you take alongside a prescription medicine.